Advanced search
Publication Cover
Cancer Management and Research Volume 14, 2022 - Issue
Submit an article Journal homepage
259
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Could Moesin Be a New Marker for Indicating Progression in Endometrial Cancer?

Elif Agacayak1 Department of Obstetrics and Gynecology, Dicle University School of Medicine, Diyarbakır, TurkeyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4215-1371
ORCID Icon,
Aysenur Keles2 Department of Pathology, Dicle University School of Medicine, Diyarbakır, Turkey
,
Ugur Deger3 Department of Obstetrics and Gynecology, Memorial Hospital, Diyarbakır, Turkey
,
Mehmet Sirin Ozcelik1 Department of Obstetrics and Gynecology, Dicle University School of Medicine, Diyarbakır, Turkey
,
Nurullah Peker1 Department of Obstetrics and Gynecology, Dicle University School of Medicine, Diyarbakır, Turkey
,
Reyhan Gunduz1 Department of Obstetrics and Gynecology, Dicle University School of Medicine, Diyarbakır, Turkey
,
Murat Akkus4 Department of Histology and Embryology, Dicle University School of Medicine, Diyarbakır, Turkey
&
Huseyin Buyukbayram2 Department of Pathology, Dicle University School of Medicine, Diyarbakır, Turkey
 show all
Pages 1247-1257 | Published online: 24 Mar 2022

References

  • Felix AS, Weissfeld JL, Stone RA, et al. Factors associated with type I and type II endometrial cancer. Cancer Causes Control. 2010;21:1851. doi:10.1007/s10552-010-9612-8
  • Mandelbaum RS, Ciccone MA, Nusbaum DJ, et al. Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy. Am J Obstet Gynecol. 2020;223:103. doi:10.1016/j.ajog.2019.12.273
  • Gallos ID, Shehmar M, Thangaratinam S, et al. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and meta analysis. Am J Obstet Gynecol. 2010;203:547.
  • Trimble CL, Kauderer J, Zaino R, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a GynecologicOncologyGroup study. Cancer. 2006;106:812. doi:10.1002/cncr.21650
  • Berryman M, Franck Z, Bretscher A. Ezrin is concentrated in the apical microvilli of a wide variety of epithelial cells whereas moesin is found primarily in endothelial cells. J Cell Sci. 1993;105:1025–1043. doi:10.1242/jcs.105.4.1025
  • Amieva MR, Furthmayr H. Subcellular localization of moesin in dynamicfilopodia, retraction fibers, and other structures involved in substrate exploration, attachment, and cell-cell contacts. Exp Cell Res. 1995;219:180–196. doi:10.1006/excr.1995.1218
  • Hiruma S, Kamasaki T, Otomo K, Nemoto T, Uehara R. Dynamics and function of ERM proteins during cytokinesis in human cells. FEBS Lett. 2017;591(20):3296–3309. doi:10.1002/1873-3468.12844
  • Bartova M, Hlavaty J, Tan Y, et al. Expression of ezrin and moesin in primary breast carcinoma and matched lymph node metastases. Clin Exp Metastasis. 2017;34:333–344. doi:10.1007/s10585-017-9853-y
  • Yu L, Zhao L, Wu H, et al. Moesin is an independent prognostic marker for ER-positive breast cancer. Oncol Lett. 2019;17:1921–1933. doi:10.3892/ol.2018.9799
  • Ferrari MV, Henriques da Costa W, Morini Matushita MA, et al. Immunohistochemical negative expression of ezrin predicts poor prognosis in clear cell renal cell carcinoma. Urol Oncol. 2020;38(3):75.e1–75.e7. doi:10.1016/j.urolonc.2019.09.011
  • Wang F, Yu T, Ma C, Zhang H, Zhang Z. The clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas: a meta-analysis. FEBS Open Bio. 2019;9:1744–1755. doi:10.1002/2211-5463.12713
  • Seagle BL, Alexander AL, Lantsman T, Shahabi S. Prognosis and treatment of positive peritoneal cytology in early endometrial cancer: matched cohort analyses from the National Cancer Database. Am J Obstet Gynecol. 2018;218:329.e1. doi:10.1016/j.ajog.2017.11.601
  • Planagumà J, Abal M, Gil-Moreno A, et al. Up-regulation of ERM/ETV5 correlates with the degree of myometrial infiltration in endometrioid endometrial carcinoma, multicenter study. J Pathol. 2005;207:422–429. doi:10.1002/path.1853
  • Ohtani K, Sakamoto H, Rutherford T, et al. Ezrin, a membrane-cytoskeletal linking protein, is highly expressed in atypical endometrial hyperplasia and uterine endometrioid adenocarcinoma. Cancer Lett. 2002;179(1):79–86. doi:10.1016/S0304-3835(01)00857-6
  • Abreu Barros FB, Assao A, Garcia NG, et al. Moesin expression by tumor cells is an unfavorable prognostic biomarker for oral cancer. BMC Cancer. 2018;18:53. doi:10.1186/s12885-017-3914-0
  • Liang L, Dong M, Cong K, Chen Y, Ma Z. Correlations of Moesin expression with the pathological stage, nerve infiltration, tumor location and pain severity in patients with pancreatic cancer. JBUON. 2019;24(3):1225–1232.
  • Wang Q, Lu X, Zhao S, et al. Moesin expression is associated with glioblastoma cell proliferation and invasion. Anticancer Res. 2017;37:2211–2218. doi:10.21873/anticanres.11556
  • Vallone C, Rigon G, Gulia C, et al. Non-coding RNAs and endometrial cancer. Genes. 2018;9(4):187. doi:10.3390/genes9040187
  • Hu Z, Zhang H, Tang L, Lou M, Geng Y. Silencing nc886, a non-coding RNA, induces apoptosis of human endometrial cancer cells-1A in vitro. Med Sci Monit. 2017;23:1317–1324. doi:10.12659/MSM.900320
  • Alam F, Mezhal F, El Hasasna H, et al. The role of p53-microRNA 200-Moesin axis in invasion and drug resistance of breast cancer cells. Tumour Biol. 2017;39(9). doi:10.1177/1010428317714634
  • Hu S, Shi X, Liu Y, et al. CD44 cross-linking increases malignancy of breast cancer via upregulation of p-Moesin. Cancer Cell Int. 2020;20:563. doi:10.1186/s12935-020-01663-4

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.